New study shows significant improved clinical accuracy with Nevisense for both US and German dermatologists

"It is an interesting article showing the positive effects of adding Nevisense and EIS as a decision support tool. Cultural differences can also be seen between German and US physicians where US dermatologist's are more afraid to miss a melanoma and therefore have a higher biopsy rate while in Germany they try to avoid unnecessary biopsies. The key message is that Nevisense can secure a better decision for the patient," says Pia Renaudin, CEO of SciBase. " It is an interesting article showing...

STOCKHOLM, 21/02/2025 (informazione.news - comunicati stampa - salute e benessere)

" " says Pia Renaudin , CEO of SciBase.

The article can be found here: https://skin.dermsquared.com/skin/article/view/3172

Pia Renaudin , CEO, tel. +46732069802, e-mail: pia.renaudin@scibase.com

Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: certifiedadviser@carnegie.se

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/scibase/r/new-study-shows-significant-improved-clinical-accuracy-with-nevisense-for-both-us-and-german-dermato,c4109216

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/new-study-shows-significant-improved-clinical-accuracy-with-nevisense-for-both-us-and-german-dermatologists-302382170.html